Over the last decade, immunotherapy has begun to drastically alter treatment paradigms for some cancers, including CRC where PD-1 blockade (3, 4) produced durable responses in patients with high levels of microsatellite instability and mismatch repair deficiency (MSI-H/dMMR) tumours. The gene discussed is PDCD1; the disease is neoplasm.